London -- The Association for the Cannabinoid Industry (ACI) and the Centre for Medicinal Cannabis (CMC) on Tuesday announced a strategic partnership with Chem ID Ltd, a provider of chemical data standardization, validation and traceability solutions. The collaboration will enable ACI and CMC's members to enhance their commitment to product authenticity, validation and quality assurance within the commercial cannabis extract and medical cannabis markets in the UK and Europe.
Chem ID's cloud-based data platform offers a comprehensive solution that ensures the integrity and security of chemical data. By using Chem ID's technology, ACI and CMC members will have the means to guarantee the authenticity and quality of their respective products, promoting consumer, retailer, regulator, patient and prescribers trust and confidence in the rapidly growing cannabis industry.
"Partnering with Chem ID allows us to take a significant step forward in ensuring the supply chain transparency and reliability of CBD products," said Dr Parveen Bhatarah, regulatory and compliance associate, ACI.
The CMC has played a vital role in advocating for positive reform within the UK’s nascent medical cannabis industry.
"At CMC, we are constantly striving to advance the standards and regulations surrounding medical cannabis," stated Professor Trevor Jones, chief scientific advisor, CMC. "Through our partnership with Chem ID, we aim to further solidify our commitment to ensuring product integrity and quality for the benefit of patients who are prescribed CBPMs [cannabis-based products for medicinal use]."
Chem ID's hardware-agnostic approach empowers various stakeholders in the cannabis industry, including brand owners, analytical labs, processors, contract manufacturers, farmers, distributors, logistical providers and regulators. The cloud-based platform offers a centralized hub for chemical data, facilitating standardized and secure communication across the supply chain.